Structures menopause evaluation and hormone therapy decision-making with risk-benefit analysis. Use when managing menopausal symptoms, evaluating HRT candidacy, or documenting menopause management.
Structures menopause evaluation and hormone therapy (HT) decision-making with risk-benefit analysis per The North American Menopause Society (NAMS), ACOG, and the Endocrine Society guidelines.
Menopause affects every woman, with the mean age of natural menopause at 51 years. Approximately 75% of women experience vasomotor symptoms (VMS), and 25% experience symptoms severe enough to affect quality of life. Hormone therapy remains the most effective treatment for VMS and genitourinary syndrome of menopause (GSM), yet the legacy of the 2002 Women's Health Initiative (WHI) created confusion about safety that persists today. The 2022 NAMS position statement clarifies that for symptomatic women under age 60 or within 10 years of menopause onset, the benefits of systemic HT generally outweigh the risks.
Proper documentation of menopausal symptom assessment, contraindication screening, risk-benefit discussion, and treatment selection is essential for medicolegal protection and quality care. Premature ovarian insufficiency (POI — menopause before age 40) requires distinct management due to increased cardiovascular and bone health risks.
| Stage | Definition | Laboratory Confirmation |
|---|---|---|
| Perimenopause (menopausal transition) | Irregular cycles with variable flow; ≥ 7-day change in cycle length | FSH not routinely needed; diagnosis is clinical |
| Menopause | 12 consecutive months of amenorrhea (no other cause) | FSH > 30–40 IU/L if diagnostic uncertainty |
| Premature ovarian insufficiency (POI) | Menopause before age 40 | FSH > 40 IU/L on two samples 4–6 weeks apart, low estradiol |
| Surgical menopause | Bilateral oophorectomy at any age | No lab needed; onset is acute |
For POI: pursue karyotype (rule out Turner mosaicism), adrenal antibodies (21-hydroxylase), thyroid function, and consider FMR1 premutation screening.
| Severity | Description |
|---|---|
| Mild | Sensation of heat without sweating; does not interfere with activity |
| Moderate | Sensation of heat with sweating; able to continue activity |
| Severe | Sensation of heat with sweating; must stop activity; may include chills, anxiety, faintness |
Document frequency (episodes per day/week), duration (average length), and impact on sleep and daily function.
GSM is progressive and does not improve without treatment. Low-dose vaginal estrogen is the first-line therapy and has minimal systemic absorption.
Document the risk-benefit discussion with the patient, including baseline breast cancer risk (use the Gail Model or Tyrer-Cuzick model).
| Regimen | Indication | Notes |
|---|---|---|
| Estrogen alone | Women with prior hysterectomy | No progestogen needed |
| Estrogen + progestogen (continuous combined) | Women with intact uterus, postmenopausal | Progestogen is mandatory to prevent endometrial hyperplasia |
| Estrogen + progestogen (cyclic) | Women with intact uterus, perimenopausal | Progestogen for 12–14 days/month; expect scheduled withdrawal bleeding |
| Low-dose vaginal estrogen | GSM symptoms only (no systemic VMS) | Minimal systemic absorption; progestogen NOT required |
| Transdermal estrogen | All candidates; preferred in VTE risk, hypertriglyceridemia, migraine | Avoids first-pass hepatic effect |
| Bazedoxifene + conjugated estrogens (Duavee) | VMS + osteoporosis prevention, intact uterus | TSEC — no additional progestogen needed |